Atea Pharmaceuticals AVIR

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
-$0.01 (-0.33%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

Relative Strength Index (RSI)

- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

- The RSI is calculated using the following formula:

RSI = 100 - (100 / (1 + RS))

Where RS is the ratio of the average gains to the average losses over a specified period.

- The default time period used is 14 days.

- RSI values range between 0 and 100.

RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

About

Business overview of Atea Pharmaceuticals (AVIR)
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).

Key Insights

Critical company metrics and information

  • Latest Closing Price

    $2.99

  • Market Cap

    $255.72 Million

  • Price-Earnings Ratio

    -1.50

  • Total Outstanding Shares

    84.46 Million Shares

  • Total Employees

    75

  • Dividend

    No dividend

  • IPO Date

    October 30, 2020

  • SIC Description

    Pharmaceutical Preparations

  • Primary Exchange

    NASDAQ

  • Type

    Common Stock

  • Headquarters

    225 franklin street, Boston, MA, 02110

  • Homepage

    https://www.ateapharma.com

Historical Stock Splits

If you bought 11 shares of AVIR before February 14, 2018, you'd have 1 share today.
Execution DateSplit Amount
February 14, 20181-for-11 (Reverse Split)

Cash Flow Statement

January 1, 2024 to December 31, 2024
MetricValue
Net Cash Flow From Investing Activities$56.10 Million
Net Cash Flow From Investing Activities, Continuing$56.10 Million
Net Cash Flow From Operating Activities, Continuing$-135.50 Million
Net Cash Flow From Financing Activities$267,000
Net Cash Flow$-79.13 Million
Net Cash Flow, Continuing$-79.13 Million

Income Statement

January 1, 2024 to December 31, 2024
MetricValue
Operating Expenses$192.95 Million
Diluted Earnings Per Share$-2
Revenues$0
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0
Depreciation and Amortization$416,000
Net Income/Loss Attributable To Parent$-168.38 Million

Comprehensive Income

January 1, 2024 to December 31, 2024
MetricValue
Other Comprehensive Income/Loss$26,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
Comprehensive Income/Loss Attributable To Parent$-168.36 Million
Comprehensive Income/Loss$-168.36 Million

Balance Sheet

January 1, 2024 to December 31, 2024
MetricValue
Wages$5.90 Million
Liabilities And Equity$464.67 Million
Other Current Liabilities$8.24 Million
Accounts Payable$4.46 Million
Equity Attributable To Noncontrolling Interest$0
Liabilities$25.80 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends

Recent Headlines From The Web

Latest news, press releases, and media coverage about AVIR from trusted financial sources
    All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

    â“’ 2025 Financhle. All Rights Reserved.